{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:40:50Z","timestamp":1789184450998,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023970","name":"LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No currently approved treatment for paediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor that targets the p19 subunit) demonstrated substantial efficacy with a favourable safety profile in treating moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of guselkumab in paediatric patients with moderate-to-severe plaque psoriasis (PROTOSTAR; NCT03451851).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase III randomized placebo-controlled study enrolled patients aged \u2265 6 to &amp;lt; 18\u2005years with moderate-to-severe plaque psoriasis. In part 1 [week (W)0\u2013W16], patients were randomized to receive guselkumab, placebo or open-label etanercept (active reference arm). At W16, part 1 patients entered a guselkumab withdrawal\/retreatment period or continued\/crossed over to receive guselkumab (W16\u2013W52). Co-primary endpoints were Investigator Global Assessment (IGA) 0\/1 and \u2265 75% improvement in Psoriasis Area and Severity Index (PASI 75) [or U.S. Food and Drug Administration-required \u2265 90% improvement in PASI (PASI 90) co-primary endpoint] responses at W16 of part 1. Part 2 evaluated continuous open-label guselkumab treatment (W0\u2013W52).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 92 and 28 patients enrolled in parts 1 and 2, respectively, 86% and 96% continued treatment through W52. In part 1, at W16, significantly higher proportions of guselkumab-treated compared with placebo-treated patients achieved IGA 0\/1 (66% vs. 16%; P &amp;lt; 0.001), PASI 75 (76% vs. 20%; P &amp;lt; 0.001) and PASI 90 (56% vs. 16%; P &amp;lt; 0.01). More than one-third of guselkumab-treated patients achieved clear skin [IGA 0: 39% vs. 4% placebo; 100% improvement in PASI (PASI 100): 34% vs. 0% placebo; both P &amp;lt; 0.01]. In part 2, at W52, 86%, 93% and 82% of guselkumab-treated patients achieved IGA 0\/1, PASI 75 and PASI 90, respectively. Through W16 of part 1, 42%, 68% and 58% of guselkumab-, placebo- and etanercept-treated patients, respectively, experienced adverse events (AEs). Rates of AEs with guselkumab were similar through W52 in parts 1 and 2; common AEs included nasopharyngitis, upper respiratory tract infection and COVID-19. No serious or opportunistic infections occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Guselkumab demonstrated significant and clinically meaningful responses in paediatric patients with moderate-to-severe plaque psoriasis, and all co-primary and major secondary endpoints were met. Safety outcomes for guselkumab in paediatric patients were similar to placebo and consistent with the established profile in adults, with no new safety signals identified. These findings support the use of guselkumab to treat paediatric patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae502","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:25:51Z","timestamp":1734708351000},"page":"618-628","source":"Crossref","is-referenced-by-count":13,"title":["Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study"],"prefix":"10.1093","volume":"192","author":[{"given":"Vimal H","family":"Prajapati","sequence":"first","affiliation":[{"name":"Dermatology Research Institute , Calgary, AB ,","place":["Canada"]},{"name":"Probity Medical Research , Calgary, AB ,","place":["Canada"]},{"name":"Skin Health & Wellness Centre , Calgary, AB ,","place":["Canada"]},{"name":"Division of Dermatology, Department of Medicine, University of Calgary , Calgary, AB ,","place":["Canada"]},{"name":"Section of Community Pediatrics, Department of Pediatrics , Calgary, AB ,","place":["Canada"]},{"name":"Section of Pediatric Rheumatology, Department of Pediatrics , Calgary, AB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke M B","family":"Seyger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Wilsmann-Theis","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Allergology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzsebet","family":"Szakos","sequence":"additional","affiliation":[{"name":"Borsod Aba\u00faj Zempl\u00e9n County University Teaching Hospital, University of Miskolc , Miskolc ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kaszuba","sequence":"additional","affiliation":[{"name":"DERMED Medical Center , Lodz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van Hartingsveldt","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Jett","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , LLC, Spring House, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , LLC, Spring House, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , LLC, Spring House, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Sinha","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , LLC, Spring House, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-8830","authenticated-orcid":false,"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Beerse ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M C","family":"DeKlotz","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , LLC, Spring House, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"2025031819362401900_ljae502-B1","doi-asserted-by":"crossref","first-page":"11128","DOI":"10.3390\/ijms231911128","article-title":"Biological treatments for pediatric psoriasis: state of the art and future perspectives","volume":"23","author":"Diotallevi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025031819362401900_ljae502-B2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"2025031819362401900_ljae502-B3","doi-asserted-by":"crossref","first-page":"944208","DOI":"10.3389\/fmed.2022.944208","article-title":"Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis","volume":"9","author":"Golhen","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025031819362401900_ljae502-B4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025031819362401900_ljae502-B5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1573400511666150504125456","article-title":"Psoriasis in children: a review","volume":"11","author":"Megna","year":"2015","journal-title":"Curr Pediatr Rev"},{"key":"2025031819362401900_ljae502-B6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr Drugs"},{"key":"2025031819362401900_ljae502-B7","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Schakel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025031819362401900_ljae502-B8","author":"Janssen Biotech"},{"key":"2025031819362401900_ljae502-B9","author":"Janssen Inc."},{"key":"2025031819362401900_ljae502-B10","volume-title":"TREMFYA subcutaneous injection 100\u2005mg syringe (guselkumab) [prescribing information]","author":"Janssen Pharmaceuticals, K.K","year":"2018"},{"key":"2025031819362401900_ljae502-B11","author":"Janssen-Cilag International, NV"},{"key":"2025031819362401900_ljae502-B12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025031819362401900_ljae502-B13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025031819362401900_ljae502-B14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-\u00adcontrolled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025031819362401900_ljae502-B15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2025031819362401900_ljae502-B16"},{"key":"2025031819362401900_ljae502-B17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025031819362401900_ljae502-B18","first-page":"260","article-title":"The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison","volume":"2","author":"Gottlieb","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"2025031819362401900_ljae502-B19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025031819362401900_ljae502-B20","first-page":"e42068","article-title":"Impact of pediatric dermatologic conditions on child and parent quality of life","volume":"15","author":"Min","year":"2023","journal-title":"Cureus"},{"key":"2025031819362401900_ljae502-B21","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged &gt; or = 8\u2005years with severe plaque psoriasis","volume":"20","author":"Landells","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2025031819362401900_ljae502-B22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5\u2005years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025031819362401900_ljae502-B23","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1111\/jdv.19309","article-title":"Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2","volume":"37","author":"Armstrong","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025031819362401900_ljae502-B24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae502\/61253632\/ljae502.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/618\/61253632\/ljae502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/618\/61253632\/ljae502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:36:38Z","timestamp":1742312198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/4\/618\/7930293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,21]]},"published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae502","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,12,21]]}}}